Efficacy of MND-2119 in Participants With Hypertriglyceridemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 580 participants.
Also called NCT03693131
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 580 participants
- Registry
-
NCT03693131
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT03693131. Randomized; quadruple masking; primary purpose treatment. Start 2018-10-27 (actual); primary completion 2019-06-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of MND-2119 in Participants With Hypertriglyceridemia
- Condition
- Hypertriglyceridemia
- Intervention (Drug)
- Icosapent (MND-2119)
- Intervention (Drug)
- Icosapent (EPADEL CAPSULES 300)
- Lead sponsor
- Mochida Pharmaceutical Company, Ltd.
Record details
- Record id
cardio:ct-nct03693131- Content hash
9dbc4af4852200ff9357a85e11cfab8118d482d6de5e00f4c80d31cc7f9c658b